Skip to main content
. 2021 May 3;8(2):e000891. doi: 10.1136/jitc-2020-000891

Figure 1.

Figure 1

Overall survival. (A) In intermediate-risk/poor-risk patients. (B) In intent-to-treat patients. (C) In favorable-risk patients. mOS, median overall survival; NE, not estimable; NIVO+IPI, nivolumab plus ipilimumab; NR, not reached; SUN, sunitinib.